Navigation Links
BioMS Medical to present at UBS Global Life Sciences Conference
Date:9/19/2008

Toronto Stock Exchange Symbol: MS

EDMONTON, Sept. 19 /PRNewswire-FirstCall/ - BioMS Medical Corp (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that Mr. Kevin Giese, President and CEO, will present at the UBS Global Life Sciences Conference in New York.

WHEN: Monday September 22nd at 10:00am (Eastern Time)

WHERE: Grand Hyatt New York, New York

About BioMS Medical Corp.

-------------------------

BioMS Medical is a biotechnology company engaged in the development and commercialization of novel therapeutic technologies. BioMS Medical's lead technology, dirucotide (MBP8298), is for the treatment of multiple sclerosis and is being evaluated in two pivotal phase III clinical trials for secondary progressive MS patients, MAESTRO-01 in Canada and Europe and MAESTRO-03 in the United States. It additionally is being evaluated for relapsing remitting MS patients in a Phase II trial in Europe entitled MINDSET-01. In December 2007, BioMS entered into a licensing and development agreement granting Eli Lilly and Company exclusive worldwide rights to dirucotide (MBP8298), in exchange for an $87 million upfront payment, milestone payments and escalating royalties on sales. For further information please visit our website at http://www.biomsmedical.com.

This press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of comp
'/>"/>

SOURCE BioMS Medical Corp.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. BioMS Medicals lead drug, dirucotide (MBP8298) for the treatment of multiple sclerosis, receives fast track designation from FDA
2. BioMS Medical announces its intention to renew a normal course issuer bid
3. BioMS Medical announces positive interim analysis on phase III trial of dirucotide (MBP8298) for multiple sclerosis
4. BioMS Medical Announces Second Quarter 2008 Results
5. BioMS Medical completes patient recruitment in phase III U.S. multiple sclerosis trial
6. BioMS Medical to present at BMO Healthcare Conference
7. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
8. BioMS Medical to present at Jefferies Healthcare Conference
9. BioMS Medical to present at 2008 BIO International Convention
10. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
11. BioMS Medical announces first quarter 2008 results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/16/2013)... May 16, 2013 Scientists at the Center ... , and the California -based ... a novel therapy for reversing memory decline in mice ... find significant cognitive improvement in advanced stage AD mice. ... for reversing cognitive decline for advanced stage AD mice, ...
(Date:5/16/2013)... 16, 2013 Reportlinker.com announces ... is available in its catalogue: ... Analysis: Therapeutic Proteins – Biosimilars, Biobetters ...   Product ... The new Competitive Intelligence Report Therapeutic ...
(Date:5/16/2013)... ON (PRWEB) May 16, 2013 DNA Genotek, ... announced ‘Spit for Africa’, a sponsorship program in conjunction with ... is designed to improve access and reduce the cost of ... projects such as the Human Heredity and Health in Africa ... the AfSHG. , The aim of the AfSHG ...
(Date:5/16/2013)... York, NY (PRWEB) May 16, 2013 ... Insights: Market Access Success for Companion Diagnostic–Drug Pairings ... key issues that biopharmaceutical manufacturers should understand when ... is gaining traction, particularly in oncology, with two ... and Zelboraf for BRAF-mutation positive melanoma. Payors are ...
Breaking Biology Technology:Elevation of Brain Magnesium Reverses Memory Deficits in Alzheimer Mice 2Elevation of Brain Magnesium Reverses Memory Deficits in Alzheimer Mice 3Competitor Analysis: Therapeutic Proteins - Biosimilars, Biobetters & Biosuperiors 2Competitor Analysis: Therapeutic Proteins - Biosimilars, Biobetters & Biosuperiors 3Competitor Analysis: Therapeutic Proteins - Biosimilars, Biobetters & Biosuperiors 4Competitor Analysis: Therapeutic Proteins - Biosimilars, Biobetters & Biosuperiors 5Competitor Analysis: Therapeutic Proteins - Biosimilars, Biobetters & Biosuperiors 6Competitor Analysis: Therapeutic Proteins - Biosimilars, Biobetters & Biosuperiors 7Competitor Analysis: Therapeutic Proteins - Biosimilars, Biobetters & Biosuperiors 8DNA Genotek Inc. Announces Spit for Africa Program 2DNA Genotek Inc. Announces Spit for Africa Program 3Market Access Expert Firm, PRMA Consulting, Launches Companion Diagnostics Handbook 2
... Micromet, Inc. (Nasdaq: MITI ), a ... treatment of cancer, inflammation and autoimmune diseases, today ... Journal of Immunotherapy (1) demonstrating the potent anti-tumor ... antigen (CEA) and to CD3 on T cells. ...
... Scientists have designed tiny new sensor structures that could ... and explosives, or in highly sensitive medical sensors, according ... Letters . , The new ,nanosensors, which are ... and US research groups, could be tailor-made to instantly ...
... Impact Systems, video is chosen as a finalist in the International ... ... Greenville, DE (PRWEB) April 7, 2009 -- Impact Systems ... (ECM) software tools and services, today announced their Compliance-in-a-Box video has ...
Cached Biology Technology:Pre-Clinical Data on CEA-specific BiTE Antibody Published in Journal of Immunotherapy Demonstrate Potent Control of Tumor Growth 2Pre-Clinical Data on CEA-specific BiTE Antibody Published in Journal of Immunotherapy Demonstrate Potent Control of Tumor Growth 3Pre-Clinical Data on CEA-specific BiTE Antibody Published in Journal of Immunotherapy Demonstrate Potent Control of Tumor Growth 4New security and medical sensor devices made possible by metallic nanostructures 2Impact Systems' Compliance-in-a-Box™ Video is Announced as "Be the Buzz of Bio" Contest Finalist 2Impact Systems' Compliance-in-a-Box™ Video is Announced as "Be the Buzz of Bio" Contest Finalist 3
(Date:5/16/2013)... use of genome-wide analysis (GWA), where the entirety of ... genomic mutations or variants which can cause health problems ... However, it can also pose major ethical problems if ... of Human Genetics (ESHG) published on line today (16 ... Genetics ., Many services based on whole genome and ...
(Date:5/16/2013)... and the manager of San Diego Zoo Global,s Central ... award. The Whitley award is an international competition ... celebrates the extraordinary achievements of some of the world,s ... selected for the award due to his efforts to ... wildlife inhabitants., HRH The Princess Royal, the charity,s patron, ...
(Date:5/16/2013)... NEW YORK , May 16, 2013 ... market research report is available in its ... Market Forecast & Opportunities, 2018 ... data protection and old security practises such ... driven the growth of biometric technologies in ...
Breaking Biology News(10 mins):European Society of Human Genetics urges caution over use of new genetic sequencing techniques 2Cameroon researcher wins prestigious 'Green Oscar' 2Cameroon researcher wins prestigious 'Green Oscar' 3Global Biometric Systems Market Forecast & Opportunities, 2018 2Global Biometric Systems Market Forecast & Opportunities, 2018 3Global Biometric Systems Market Forecast & Opportunities, 2018 4Global Biometric Systems Market Forecast & Opportunities, 2018 5Global Biometric Systems Market Forecast & Opportunities, 2018 6Global Biometric Systems Market Forecast & Opportunities, 2018 7
... with basic scientists from the University of California, Irvine ... for normal development of the reproductive, olfactory and circadian ... report to appear in the Proceedings of the National ... gene called PROK2 (prokineticin 2) in human siblings with ...
... mind,s growth -- but it does not have to stop ... of adult monkeys. A team of neuroscientists has ... at which new neural cells form in the hippocampus region ... associated with both learning and memory. While other research groups ...
... service, developed in the framework of an ESA-supported project, ... across Europe in order to ensure the more efficient ... European Union (EU) must be registered with the national ... (EPPO), which requires efficiency data derived from field trials. ...
Cached Biology News:Study identifies pathway required for normal reproductive development 2Study identifies pathway required for normal reproductive development 3Brain cell growth diminishes long before old age strikes, animal study shows 2
...
IHC detection kit for BrdU in cells and tissues...
The Hybrid Hunter Yeast Two-Hybrid System uses the activation of reporter genes to indicate positive protein-protein interactions. Two reporters are used an auxotrophic marker and lacZ....
Request Info...
Biology Products: